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Abstract: Recent studies have shown the ability of electrochemical methods to sense and
determine, even at very low concentrations, the presence and quantity of molecules or analytes
including pharmaceutical samples. Furthermore, analytical methods, such as high-pressure liquid
chromatography (HPLC), can also detect the presence and quantity of peptides at very low
concentrations, in a simple, fast, and efficient way, which allows the monitoring of conjugation
reactions and its completion. Graphite/SiO2 film electrodes and HPLC methods were previously
shown by our group to be efficient to detect drug molecules, such as losartan. We now use these
methods to detect the conjugation efficiency of a peptide from the immunogenic region of myelin
oligodendrocyte to a carrier, mannan. The HPLC method furthermore confirms the stability of
the peptide with time in a simple one pot procedure. Our study provides a general method to
monitor, sense and detect the presence of peptides by effectively confirming the conjugation efficiency.
Such methods can be used when designing conjugates as potential immunotherapeutics in the
treatment of diseases, including multiple sclerosis.
Keywords: mannan; peptide; conjugation; MOG35-55; Graphite/SiO2 electrode; voltammetry; HPLC;
multiple sclerosis; immunotherapy; vaccine
1. Introduction
Voltammetric techniques, including differential pulse voltammetry (DPV) and cyclic voltammetry
(CV), as well as high-performance liquid chromatography (HPLC), were applied to identify and
detect a peptide to its conjugated carrier. This study describes for the first time an alternative, fast,
low cost and reliable method for the adequate and reliable determination of an active pharmaceutical
ingredient (API) in the biocompatible matrix. The performance of the voltammetric techniques is
strongly dependent on the performance of the working electrode used. Film electrodes, such as the
graphite/SiO2 used in this study, are being used in electrochemistry, as it has a number of advantages
over the standard metallic and glass carbon electrodes. These include ease of manufacture requiring
lower temperatures, low cost, the high surface area that could be rapidly renovated, simple handling,
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and their increased conductivity in a wide range of potentials. In addition, these techniques exhibit
a wide range of anodic and cathodic peaks and great electrocatalytic activity and stability. All these
features are crucial for the correct choice of a working electrode, especially when direct electrochemistry
is conducted [1]. We recently demonstrated that these film electrodes modified or not, could be used
for electrochemical drug sensing, for validation in food chemistry, and for the immobilization of heme
proteins for studying protein/electrode interaction [2–4]. The electrochemical analytical methods were
recently applied effectively in the detection of anti-hypertensive drug losartan [3] and have applied this
method to detect peptides in peptide-carrier conjugates. The peptide used was the multiple sclerosis
(MS) immunogenic peptide from myelin oligodendrocyte (MOG35-55).
Numerous methods have been established for the analytical determination of drugs at
low concentrations, using state of the art systems, such as HPLC, high-performance thin-layer
chromatography and capillary electrophoresis/capillary electrochromatography [3]. Although these
methods provide very accurate and reliable data, they are costly, time consuming, and involve
the use of expensive equipment and consumables. In addition, sample pre-treatment is usually
necessary. In this sense, electrochemical methods have emerged as low cost, reliable alternatives for the
characterization of peptides and drugs. Different electrochemical techniques, involving voltammetry
or potentiometry, have been implemented for drug analysis, as they offer ease of preparation and
operation, high sensitivity, fast response time, high quantification and detection limits, reasonable
selectivity, wide linear range, and are cost effective [3]. In this regard, we applied voltammetry
techniques to monitor the conjugation of a peptide to its carrier, for the first time as a proof of
concept study.
MS is regarded an autoimmune disease where immune cells (such as, Th1, Th17, macrophages,
B cells) and their constituents (pro-inflammatory cytokines) are involved in the pathophysiology of
the disease, with destruction of myelin sheath and loss of neurological function [5–10]. In an attempt
to develop immunotherapeutics against MS using immunogenic/agonist peptides is to either alter the
peptide to make it an antagonist [11–16], make it cyclic [17–19], or conjugate it to an appropriate carrier,
which would deliver the peptide in such a manner to either induce tolerance, or alter the profile of
T cells from pro-inflammatory (Th1) to anti-inflammatory (Th2) [13–15]. One approach which our
team has developed, is to use mannan, a poly-mannose carrier conjugated to MS peptides [20–24].
This approach was developed over 25 years ago by the group of Apostolopoulos et al., to be effective
in targeting peptides and proteins to dendritic cells in a number of different cancer vaccine models,
some of which were translated to human clinical trials [25–32]. As such, mannan was used as a carrier
and conjugated to immunodominant MS peptides including MBP83-99, PLP139-141, and MOG35-55 or
their analogues, and were shown in animal models to tolerize T cells or switch Th1 cells to Th2
cells, depending on the peptide analogue used and showed stimulation of Th2 cells in peripheral
blood mononuclear cells from patients with MS [17,21,33–35]. The conjugation of mannan, in its
oxidized form (OM), to MOG35-55 peptide (MOG35-55 was used as an example in this study) via a
(Lys-Gly)5 linker [(KG)5] was used and evaluated (OM-(KG)5-MOG35-55 conjugate) using voltammetric
techniques [1–4,36–38]. The conjugation between OM and peptide (MOG35-55) occurs via formation
of Schiff bases between the free amines of the linker (KG)5 and aldehydes of OM. The synthesis and
efficacy of these conjugates have been described in numerous studies [23,24,39,40]. However, the extent
of conjugation and the redox condition of the participating sugars, such as mannan, are most times
assessed by high cost, complicated and lengthy analytical methods, such as capillary electrophoresis
and polyacrylamide gel electrophoresis [23,24,39,40].
Among the approaches used in recent years for the immunomodulation of MS, the conjugation of
mannan with myelin peptides has shown much promise, including that of OM-(KG)5-MOG35-55,
which induces tolerance in mice, providing a promising conjugate for further studies.
The electrochemical and HPLC analysis for identification of peptides or their mutants in mannan
based conjugates requires specialized techniques, which differ significantly from those methods used
for small molecules. In this study, novel analytical methods were developed and applied, that clearly,
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sense, detect, and confirm the conjugation of OM with MOG35-55. Further, this study makes it possible
to accurately evaluate the stability of the peptide component in the conjugate using HPLC [41,42].
2. Materials and Methods
2.1. Materials
Sodium metasilicate (Na2SiO3) (SiO2, 50–53%), NaH2PO4, mannan isolated from yeast cells
(Saccharomyces cerevisiae), potassium ferricyanide, ferrocyanide, and potassium chloride were obtained
from Sigma Aldrich Chemie GmbH (Taufkirchen, Germany). MOG35-55 and MOG37-55 peptides
were supplied by NewDrug S.A., Patras Science Park, Greece and purchased from China peptides
Inc. The peptide analogue (Lys-Gly)5-MOG35-55, referred as (KG)5-MOG35-55, was synthesized
using standard peptide chemistry techniques and previously published by our group. Briefly,
Fmoc/tBu methodology was used which included 2-chlorotrityl chloride resin (CLTR-Cl) and Na-Fmoc
(9-fluorenylmethyloxycarboxyl) side chain protected amino acids [43,44]. The purity of the peptides
were shown to be >97% by analytical HPLC. Graphite powder (synthetic, APS 7–11 µm, 99%) was
obtained from Alfa Aesar. Soda lime glass slides (75 mm × 25 mm × 1.1 mm), with 15 Ohm/sqr Indium
Tin Oxide (ITO) coating were obtained from PsiOTec, UK. All chemicals were of analytical grade and
used without the need for further purification. All solutions were prepared in deionized water with
resistance R = 18 MΩ cm.
2.2. Graphite/SiO2 Film Electrodes Preparation
The graphite/SiO2 film electrodes were prepared as described [2,3]. Briefly, silicate liquid polymer
(50% Na2SiO3; pH 12–13) was gently mixed with 20% graphite powder at 23 ◦C, until the mixture
became homogeneous and acquired a “sticky” texture. The mixture underwent ultrasonication for
2 min for the graphite powder to be fully soluble, and 100 µL of the silicate/graphite suspension were
applied on the surface of a conductive ITO glass slide using the “Doctor Blade” technique. Prior to
the deposition of the silicate/graphite suspension, the ITO glass slides were cleaned in a detergent
solution using an ultrasonic bath for 15 min, and then rinsed with 18 MΩ distilled water and ethanol.
Each glass slide was masked with 3M Magic Scotch tape (thickness 62.5 µm; type 810), in order to
control the width and the thickness of the mixture spread area. For each graphite/SiO2 film deposition,
one layer of tape was used which provided a size 1 × 1 cm2 and film thickness of ~66 µm. The films
were allowed to dry for 30 min in a class 4000 room, prior to placing them in a preheated oven (330 ◦C)
for 100 min. If required, the liquid suspension could be stored in an insulated flask at 25 ◦C for later
usage. The resulting ITO substrates with the deposited graphite/SiO2 films were cut in 10 mm × 25 mm
pieces before use.
2.3. Characterization of Graphite/SiO2 Film Electrodes
Field emission scanning electron microscopy (FE-SEM) using an FEI inspect microscope (25 kV)
was used to determine morphology and thickness of the Graphite/SiO2 film. The films were prepared
by AU sputtering to increase the conductivity of the samples. Energy dispersive spectroscopy EDS
was also used for the elemental analysis of the Graphite/SiO2/ITO films.
2.4. Preparation of (KG)5-MOG35-55 Peptide
MOG35-55 agonist peptide was synthesized in our labs, >97% purity, with (KG)5 extended at the
N-terminus of the peptide. Peptide was prepared using our methods, either by coupling, catalyzed
by microwave radiation in a CEM Liberty microwave system or by using the conventional step by
step procedure by solid phase peptide methods (as described in [45]). (KG)5-MOG35-55 peptide was
also purchased by China Peptides Inc. In house synthesized peptides and purchased peptides were
confirmed by HPLC and Mass Spectroscopy for purity and identity.
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2.5. Preparation of Oxidized Mannan
Mannan (14 mg) was dissolved in 1 mL phosphate buffer (0.1 M sodium phosphate, pH 6.0),
and was oxidized using 0.1 M sodium periodate and incubated at 4 ◦C for 1 h, after which 10 µL
ethanediol was added for 30 min at 4 ◦C. Oxidized mannan (OM) was passed through a PD-10 column
(Sigma Aldrich Chemie) pre-equilibrated in sodium bicarbonate buffer (sodium carbonate: Sodium
bicarbonate, pH 9.0). Two ml of OM fraction (7 mg/mL) was collected and kept in the dark.
2.6. Conjugation of Oxidized Mannan to Peptide
To the OM fraction (2 mL; 7 mg/mL, sodium bicarbonate pH 9.0 buffer), 1 mg of (KG)5-MOG35-55
peptide was added and allowed to react overnight in the dark at 23 ◦C. A list of peptides and conjugates
are summarized in Table 1.
Table 1. Peptides and conjugates used in this study.
Acronym Specification
MOG35-55 Myelin oligodendrocyte glycoprotein immunogenic epitope, region 35–55
MOG37-55 Myelin oligodendrocyte glycoprotein immunogenic epitope, region 37–55
(KG)5-MOG35-55 Peptide analogue MOG35-55 with (KG)5 at the N-terminus
OM-(KG)5-MOG35-55 Oxidized mannan conjugated to (KG)5-MOG35-55
KG, lysine glycine; MOG, myelin oligodendrocyte glycoprotein; OM, oxidized mannan.
2.7. Monitoring of Conjugation by HPLC
We used a Waters 2695 HPLC (Alliance) system with a photodiode array detector equipped
with a Lichrosorb RP-18 reversed phase analytical column (C18 35 µm, 4.6 × 50 mm PIN 186003034).
Analysis was achieved with stepped linear gradient of solvent A (0.08% TFA in H2O) and in solvent
B (0.08% TFA in 100% acetonitrile) for 30 min with a flow rate 3 mL/min. The conjugation of OM
with (KG)5-MOG35-55 peptide was evaluated by HPLC. The (KG)5-MOG35-55 HPLC peak disappeared
within six hours indicating completion of conjugation to OM.
2.8. Electrochemical/Electrocatalytic Measurements
Electrochemical measurements were conducted using an Autolab PGStat-101 potentiostat
(Metrohm, Utrecht, The Netherlands). The electrochemical cell comprised of a 10 mL, three-electrode
stirring glass cell with a Teflon cap, a platinum mesh flag as the counter electrode, a Ag/AgCl/KClsat
reference electrode and a Graphite/SiO2 film on ITO conducting glass as the working electrode.
The electrolyte contained a solution of NaH2PO4 (10 mM; pH 7.0), which was deoxygenated with
argon prior to any measurements and an argon atmosphere was kept throughout the measurements.
The DPV measurements took place in a potential range between −1 to +0.05 V. The optimized
parameters of DPV correspond to a step potential at 5 mV, amplitude of 50 mV, modulation time of
25 ms with scan rate 100 mV s−1 and a frequency of 50 Hz. All potentials are reported against Ag/AgCl
and all experiments were carried out at 23 ◦C.
3. Results and Discussion
3.1. FE-SEM Characterization
The general thickness and surface morphology of the graphite/SiO2 films were demonstrated by
FE-SEM. The top-view of the FE-SEM image (Figure 1a) shows that the surface of the graphite/SiO2 film
is rough and non-uniform with many wrinkles. It exhibits increased porosity and a high effective surface
area. Figure 1b presents the cross section of a graphite/SiO2 film electrode, with an estimated film
thickness of ~65 µm as set by the adhesive tape used; the EDS for a graphite/SiO2 film carried out during
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the FE-SEM analysis is shown in the Supplementary Materials (SM, Figure S1). The characteristic
peaks of Na, O, and Si, due to the use of silicate glue (Na2SiO3), are presented in high intensity, thus,
the peak of C is presented in lower intensity. Hence, the results validate the reduced concentration of
carbon in the mixture used for the fabrication of the graphite/SiO2 films.
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3.3. Electrochemical Analysis Showing Conjugation of (KG)5-MOG35-55 to OM
Electrochemical characteristics of the graphite/SiO2 film electrode were investigated by CV.
Figure 3a shows the electrochemical behavior of a bare graphite/SiO2 film electrode in a solution of 0.1
M KCl and 5 mM of [Fe(CN)6]3−/4− through CV in the potential range of +1 to −1 V at different scan
rates. Figure 3b shows the currents (anodic and cathodic) from the plots of I vs. square root of scan
rate (v1/2). Straight lines form for both the anodic and cathodic currents, confirming that a diffusional
process has occurred in the reaction of ferrocyanide/ferricyanide. In addition, these results confirm that
fast electron transfer occurs on the Graphite/SiO2 film electrode due to its increased conductivity and
surface area. In order to calculate the electroactive surface area of the film electrode, the Randles-Sevcik





×A×D1/2 × n3/2 ×C × v1/2 (1)
where ip corresponds to the maximum current (in Amperes), n is the number of electrons transferred
(n = 1), D is the diffusion coefficient (cm2 s−1) of [Fe(CN)6]3−/4− solution (7.6 × 10−6 cm2 s−1) [37], A is
the electrode area (cm2), C is the concentration (molcm−3) and v is the scan rate (mV s−1) and thus the
electroactive surface area of the graphite/SiO2 was estimated to be 0.0039 cm2.
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Figure 3. Cyclic voltammograms (CVs) of (a) a bare graphite/SiO2 film electrode in 0.1 M KCl solution
containing 5 mM of [Fe(CN)6]3−/4− at different scan rates. (b) Plot of anodic and cathodic peak current
(Ipa/Ipc) vs. square root of scan rate (v1/2). (c) A bare graphite/SiO2 film electrode in 10 mM NaH2PO4,
pH 7.0 at different scan rates and (d) the OM-(KG)5-MOG35-55 conjugate on graphite/SiO2 in 10 mM
NaH2PO4, pH 7.0 at different scan rates under an Argon atmosphere.
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The electrochemical behavior of the graphite/SiO2 film electrode was then investigated in the
presence and absence of the MS myelin epitope peptide vaccine (OM-(KG)5-MOG35-55). Figure 3c shows
the effect of scan rate of a bare graphite/SiO2 electrode, before the detection of the OM-(KG)5-MOG35-55,
at a scan rate range of 0.01 to 0.1 V s−1. All electrochemical experiments were performed in a peptide
free, anaerobic 10 mM NaH2PO4 (pH 7.0). The bare graphite/SiO2 film electrode shows the characteristic
charging/de-charging currents, and no cathodic or anodic peaks are observed even at the slowest scan
rate (0.01 V s−1). One of the advantages of using graphite paste electrodes is the increased conductivity,
which allows a broader study of redox reactions occurring at very high or low biases (ranging from +1
V to −1 V). Further, the slower scan rate applied, the smaller the resulting current is obtained. Figure 3b,
on the other hand, showing the CVs of OM-(KG)5-MOG35-55 on the graphite/SiO2 film electrode,
exhibits not only the characteristic charging/discharging currents assigned to electron injection into
sub-band gap/conduction band states of the graphite/SiO2 electrode, but also two reduction peaks
around −0.22 V and −0.67 V and a broad re-oxidation peak at −0.1 V.
The redox peak currents were shown to be proportional to the scan rate, characteristic of
quasi-reversible behavior. The rate of reaction between the graphite/SiO2 electrode and the conjugate,
OM-(KG)5-MOG35-55 was not fast enough to maintain equal concentrations of oxidized and reduced
species at the surface of the electrode. In addition, the CV responses were shown to be stable, with the
waveforms being unperturbed after being scanned several times, whilst no other consumption of the
complex occurred nor other undesirable reactions in the phosphate buffer took place.
In Figure 3d, the two cathodic peaks at−0.27 V and−0.7 V and the wide anodic peak approximately
at −0.1 V observed are due to the presence of the OM-(KG)5-MOG35-55. The two cathodic peaks
correspond to the linker molecule (KG)5 used to conjugate the MOG35-55 peptide to OM, that contains
5 lysines and 5 glycines to its structure. Thus, the cathodic peaks attributed to the presence of
lysines. On the other hand, the wide oxidation peak occurred probably due to superfluity of the free
(KG)5-MOG35-55 peptide that was not able to conjugate to OM and created the final complex of the
OM-(KG)5-MOG35-55 conjugate.
The CVs of the constituents of the OM-(KG)5-MOG35-55 conjugate are shown in Figure 4. According
to Figure 4a, as mentioned earlier, the bare graphite/SiO2 film electrode exhibited no reduction or
oxidation peaks which is consistent with the currents being limited by the graphite conductivity at
the voltage biases reported herein. On the other hand, the CV of the film electrode in the presence
of mannan in 0.1 M buffer exhibited an oxidation peak at approximately 0.5 V, and the CV of the
film electrode in the presence of 0.002 mg/mL OM displayed a slight cathodic peak at −0.56 V and
the characteristic anodic peak at −0.1 V. At the same time, the electrochemical behavior of peptides
MOG35-55 and MOG37-55 were examined. The main difference between these two peptides is that the
MOG35-55 peptide contained and additional linker with 5 lysines (KG)5, whilst the MOG37-55 peptide
included a linker, which only contained 1 lysine. This was confirmed in Figure 4b, which displays the
CVs of the Graphite/SiO2 film electrode in the presence of each peptide. The two cathodic and anodic
peaks observed are due to the presence of the lysine residues, however, the CV scan of the MOG35-55
peptide exhibits a higher current and a wider electrochemical window compared to the CV scan of
MOG37-55 peptide, as the latter contained only 1 lysine residue.
DPV is a more sensitive approach compared to CV and hence, has been extensively used as a
more sensitive method for the detection of molecules in low concentration [38]. In Figure 5, the DPVs
are recorded for the bare film electrode, as well as for each part that constitutes the final structure of
OM-(KG)5-MOG35-55 conjugate on the Graphite/SiO2 working electrode. As can be seen in Figure 5a,
the bare graphite/SiO2 is free of any redox peaks. However, in Figure 5b, there are two peaks which
correspond to (KG)5-MOG35-55 peptide, approximately at −0.65 V and −0.27 V, respectively. Figure 5c
shows the DPV of mannan (in 0.1 M phosphate buffer) on the surface of the film electrode, displaying
a clear sharper peak at around −0.26 V. The last step in order to evaluate the conjugation of peptide
(KG)5-MOG35-55 with OM via DPV measurements is depicted in Figure 5d with a clear and distinct peak
at−0.28 V and a shoulder peak at−0.62 V, which are actually due to the presence of OM-(KG)5-MOG35-55
Brain Sci. 2020, 10, 577 8 of 13
on the graphite/SiO2 film electrode (after the addition of 0.002 mg/mL of OM). This is a proof of concept
study, and we intend to further study the quantification of this and other conjugates, focusing on the
limit od detection (LOD) of these conjugates using voltammetric techniques.
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more sensitive method for the detection of molecules in low concentration [38]. In Figure 5, the DPVs 
are recorded for the bare film electrode, as well as for each part that constitutes the final structure of 
OM-(KG)5-MOG35-55 conjugate on the Graphite/SiO2 working electrode. As can be seen in Figure 5a, 
the bare graphite/SiO2 is free of any redox peaks. However, in Figure 5b, there are two peaks which 
correspond to (KG)5-MOG35-55 peptide, approximately at −0.65 V and −0.27 V, respectively. Figure 5c 
shows the DPV of mannan (in 0.1 M phosphate buffer) on the surface of the film electrode, displaying 
a clear sharper peak at around −0.26 V. The last step in order to evaluate the conjugation of peptide 
(KG)5-MOG35-55 with OM via DPV measurements is depicted in Figure 5d with a clear and distinct 
peak at −0.28 V and a shoulder peak at −0.62 V, which are actually due to the presence of OM-(KG)5-
MOG35-55 on the graphite/SiO2 film electrode (after the addition of 0.002 mg/mL of OM). This is a proof 
of concept study, and we intend to further study the quantification of this and other conjugates, 
focusing on the limit od detection (LOD) of these conjugates using voltammetric techniques. 
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Figure 5. Differential pulse voltammetry (DPVs) comparison of (a) a bare graphite/SiO2 film electrode,
(b) (KG)5-MOG35-55, (c) mannan, and (d) OM-(KG)5-MOG35-55 conjugate on graphite/SiO2 electrode in
10 mM NaH2PO4, pH 7.0.
3.4. Complete Conjugation between (KG)5-MOG35-55 Peptide to OM is Monitored by HPLC
Contrarily to the conjugation of MOG35-55 peptide with mannan, which did not occur, the reaction
of (KG)5-MOG35-55 with mannan (oxidized or not) resulted in gradual conjugation of (KG)5-MOG35-55
peptide within 6 h depicted in the gradual loss of the HPLC peak during this period (Figure 6).
The amino groups of lysine residues within (KG)5 forms a Schiff base reaction with the aldehyde
groups of OM (resulting after the oxidation of mannan). The (KG)5-MOG35-55 peptide peak at 9.62
gradually disappears within this period, showing complete conjugation of (KG)5-MOG35-55 peptide to
OM. Figure 6b shows the completion of conjugation within six hours.
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3.6. annan-Peptide Conjugate
In the OM-(KG)5-MOG35-55 conjugate, unreacted aldehyde groups are necessary to immunoregulate
the peptide to dendritic cells. This is a result of ethylene glycol addition to blockade further oxidation,
and in line with previous studies on MUC1-mannan conjugates in cancer research, which required aldehyde
groups in order to activate dendritic cells [39]. The matrix also contains intact mannose units, not oxidized,
necessary to bind to the mannose receptor of the dendritic cells and their activation via toll-like receptor
4 [49–52]. In particular, the procedure we followed to produce the mannan-peptide conjugate allows: (i) the
presence of antigen peptide MOG35-55 connected with aldehyde groups of the OM through immune bonds
(Schiff base) with the amino groups of the lysine side chain in the (KG)5-MOG35-55 peptide. The peptide-OM
conjugate is delivered to dendritic cells via the mannan scaffold for regulation of the immune system; (ii) the
presence of unreacted aldehyde groups are necessary to modulate dendritic cells; and (iii) the presence intact
mannose units, not oxidized, necessary to bind to the mannose receptor of the dendritic cells.
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3.7. Chemistry of the Mannose Cleavage
The cis-diols can form a cyclic complex upon oxidation with strong oxidizing agents as periodate.
This allows the cleavage of the bond between the two carbons bearing the two hydroxyl groups, leading
to the formation of aldehyde groups. Mannose is a carbohydrate, which holds two hydroxyl groups at
positions 2,3 of the ring in a cis- position. This allows the oxidizing agent sodium periodate to form a
cyclic complex, which finally leads to cleavage of the carbon-carbon bond bearing the cis-hydroxyl
groups. This complex cannot be formed if the hydroxyl groups at the adjacent carbon atoms are in a
trans position and subsequently this carbon-carbon bond cannot be cleaved. The formation of the cyclic
mannose-periodate complex is leading finally to the cleavage of the ring and the formation of the two
aldehyde groups. These groups react with the amino groups of the five lysines of the (KG)5-MOG35-55
to form double bond imines (Schiff base reaction) thus, the MOG35-55 peptide attached to the mannan
scaffold. Figure 7 shows the mechanism of cis diol cleavage.
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4. Conclusions
We developed and confirm an analytical electrochemical method for monitoring the conjugation
reaction of peptides to the carrier mannan; (KG)5-MOG35-55 was used as the peptide example in this
study. Peptide-OM conjugates can serve as potential vaccine candidates as has previously been shown
by the group for cancer models and more recently in MS models. Electrochemical voltammetric
techniques and HPLC experiments were used to confirm the conjugation of (KG)5-MOG35-55 to the
aldehy e groups of OM. It is shown that v ltamm tric t chnique and HPLC can be used to monitor
the conjugation efficiency of peptide-carrier conjugates.
Supple entary M terials: The following are availabl online at http://www.mdpi.com/2076-3425/10/9/577/s1.
Figure S1: EDS elemental microanalysis of a Graphite/SiO2 film electrode.
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